摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 3-(trimethylsilyl)-1H-pyrazole-5-carboxylate | 36960-47-1

中文名称
——
中文别名
——
英文名称
ethyl 3-(trimethylsilyl)-1H-pyrazole-5-carboxylate
英文别名
ethyl 5-trimethylsilyl-1H-pyrazole-3-carboxylate
ethyl 3-(trimethylsilyl)-1H-pyrazole-5-carboxylate化学式
CAS
36960-47-1
化学式
C9H16N2O2Si
mdl
——
分子量
212.324
InChiKey
RXCDGYSBSBEJHK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    142 °C
  • 沸点:
    307.7±27.0 °C(Predicted)
  • 密度:
    1.06±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.13
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    55
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of pyrazoles through catalyst-free cycloaddition of diazo compounds to alkynes
    作者:Daniela Vuluga、Julien Legros、Benoît Crousse、Danièle Bonnet-Delpon
    DOI:10.1039/b812242c
    日期:——
    The synthesis of pyrazoles via1,3-dipolar cycloaddition of diazo compounds to alkynes proceeds easily by heating. With α-diazocarbonyl substrates the reactions are conducted under solvent-free conditions affording the pyrazole products in high yields without any work up or purification.
    的合成 吡唑类 通过1,3-偶极环加成 的 重氮化合物 到 炔烃加热容易进行。对于α-重氮羰基底物,反应在溶剂无条件提供 吡唑 高收率的产品,无需任何后处理或 纯化。
  • KINASE INHIBITORS
    申请人:RESPIVERT LIMITED
    公开号:US20150210722A1
    公开(公告)日:2015-07-30
    There are provided compounds of formula (I), wherein R 1 to R 5 , X 1 , X 2 , Ar, L, A, A 1 , E and G have meanings given in the description, which compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    提供了化合物的结构式(I),其中R1至R5,X1,X2,Ar,L,A,A1,E和G的含义如描述所示,这些化合物具有抗炎活性(例如,通过抑制p38丝裂原活化蛋白激酶家族中的一个或多个成员;Syk激酶;以及酪氨酸激酶Src家族的成员之一)并且可用于治疗,包括在药物组合中,尤其是用于治疗包括肺部、眼部和肠道炎症疾病在内的炎症性疾病。
  • Steric redirection of alkylation in 1 H -pyrazole-3-carboxylate esters
    作者:Stephen W. Wright、Eric P. Arnold、Xiaojing Yang
    DOI:10.1016/j.tetlet.2017.12.052
    日期:2018.1
    The alkylation of ethyl 1H-pyrazole-3-carboxylate with a variety of alkylating agents in the presence of K2CO3 was found to largely favor the formation of ethyl 1-substituted pyrazole-3-carboxylates. The alkylation could be sterically redirected by the use of a triphenylsilyl group (ethyl 3-(triphenylsilyl)-1H-pyrazole-5-carboxylate) to provide synthetically useful yields of ethyl 1-substituted-3-
    发现在K 2 CO 3存在下用各种烷基化剂将1 H-吡唑-3-羧酸乙酯烷基化大大促进了1-取代的吡唑-3-羧酸乙酯的形成。烷基化可通过使用三苯基甲硅烷基(3-(三苯基甲硅烷)-1是空间重定向ħ唑-5-羧酸酯),以提供乙基1-取代的-3-(三苯基甲硅烷)的合成有用的产率-1 ħ -唑-5-羧酸盐。可以用Bu 4 NF除去三苯基甲硅烷基。其他三有机甲硅烷基(TMS,TES,TBDMS)无法提供明显的重定向,而TIPS被证明对原去甲硅烷基化不起反应。
  • Development of novel androgen receptor antagonists based on the structure of darolutamide
    作者:Qian Xu、Zixiong Zhang、Chenchao Huang、Qiqi Bao、Rongyu Zhang、Meng Wu、Xiaohui Xiao、Xiaoli Han、Xiaoyu Li、Jinming Zhou
    DOI:10.1016/j.bioorg.2022.105829
    日期:2022.7
    antiandrogen because of its unique chemical structure and good activity against androgen receptor (AR). Herein, the structure-activity relationship of ODM-201 was studied, and 37 analogues were synthesized. Half of them exhibited similar or better anti-AR transcriptional activity compared to ODM-201. In addition, the inhibitory activity of compound 28t against the two resistant mutants (AR-F876L and AR-T877A)
    雄激素信号通路在前列腺癌(PCa)的发生发展中发挥着重要作用,而抗雄激素药物是治疗前列腺癌最有效的疗法之一。Darolutamide 4 (ODM-201) 是一种很有前途的第二代抗雄激素药物,因为它具有独特的化学结构和对雄激素受体 (AR) 的良好活性。本文研究了ODM-201的构效关系,合成了37个类似物。与 ODM-201 相比,其中一半表现出相似或更好的抗 AR 转录活性。此外,化合物28t的抑制活性对两种抗性突变体(AR-F876L 和 AR-T877A)的抗性优于 ODM-201。该研究为进一步优化ODM-201和开发抗CRPC药物提供了新线索。
  • PYRAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS
    申请人:MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    公开号:US20150057247A1
    公开(公告)日:2015-02-26
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.
    本文提供了公式(I)的化合物,以及其药学上可接受的盐,其中取代基如规范中所披露。这些化合物及其含量的制药组合物对于治疗退行性疾病和紊乱是有用的。
查看更多